In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 |
| 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
Revenues: | | | | | | | | |
Finance receivable interest income, including fees | 36.8 | 34.3 | 35.5 | 35.2 | 36.1 | 41.0 | 39.3 | 37.9 |
Pharmaceutical development | 5.4 | 5.4 | 5.5 | 10.7 | 5.8 | 16.2 | 16.1 | 13.7 |
Other | 0.1 | 0.1 | 0.5 | 0.7 | | 0.7 | 0.7 | |
Total revenues | 42.3 | 39.8 | 41.5 | 46.6 | 42.6 | 57.9 | 56.2 | 52.1 |
Total revenues growth | -0.6% | -31.3% | -26.1% | -10.5% | -19.9% | 49.2% | 52.8% | 48.0% |
Costs and expenses: | | | | | | | | |
Interest expense | -0.7 | -0.4 | -0.3 | -0.3 | -0.3 | -0.3 | -0.4 | -0.4 |
Pharmaceutical manufacturing, research and development expense | 5.8 | 5.8 | 7.0 | 6.9 | 7.6 | 7.7 | 7.3 | 6.5 |
Depreciation and amortization expense | 2.6 | 2.5 | 2.6 | 2.7 | 2.9 | 3.1 | 4.1 | 5.8 |
General and administrative | 12.3 | 12.3 | 13.0 | 14.3 | 13.6 | 13.9 | 13.6 | 12.2 |
Income from operations | 36.7 | 33.8 | 39.5 | 37.0 | 37.1 | 36.0 | 31.0 | 27.0 |
|
Other income (expense), net | | | | | | | | |
Unrealized net gain (loss) on warrants | 1.0 | 0.1 | 0.4 | 0.2 | -1.8 | -0.7 | 0.3 | 1.2 |
|
Gain on foreign currency transactions | | | | | | | | |
Income before income tax expense | 14.1 | 9.5 | 9.5 | 22.3 | 16.5 | 33.2 | 33.0 | 27.9 |
Income tax expense | -3.9 | -5.2 | -4.0 | 5.3 | 3.9 | 7.2 | 7.1 | 3.6 |
Tax rate | -27.8% | | -42.1% | 23.8% | 23.5% | 21.7% | 21.5% | 13.1% |
Net income | 18.0 | 14.6 | 13.5 | 17.0 | 12.6 | 26.0 | 25.9 | 24.2 |
|
Net income per share | | | | | | | | |
Basic | $1.41 | $1.14 | $1.05 | $1.33 | $0.99 | $2.04 | $2.03 | $1.89 |
Diluted | $1.40 | $1.13 | $1.04 | $1.31 | $0.97 | $2.02 | $2.01 | $1.88 |
|
Basic | 12.8 | 12.8 | 12.8 | 12.8 | 12.8 | 12.8 | 12.8 | 12.8 |
Diluted | 12.8 | 12.9 | 12.9 | 12.9 | 12.9 | 12.9 | 12.8 | 12.8 |